Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark H Flasar

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Inflammatory Bowel Diseases|February 26, 2016
Biological and Immunomodulator Use in Crohn's Disease in a Medicaid PopulationMark H Flasar, Jingdong Chao, A Burak Ozbay, et al.
Gastroenterology & Hepatology|August 29, 2017
A Health Survey of Gastroenterologist Prescribing Practices of Adalimumab for Treatment of Crohn's Disease: Final ResultsSamantha Zullow, Mark H Flasar, Deborah Greenberg, et al.
World Journal of Clinical Oncology|October 26, 2017
Characteristics of <i>Clostridium difficile</i> infection in patients hospitalized with myelodysplastic syndrome or acute myelogenous leukemiaKamini Shah, Bryan F Curtin, Christopher Chu, et al.
Inflammatory Bowel Diseases|April 20, 2013
Step up versus early biologic therapy for Crohn's disease in clinical practiceLeyla J Ghazi, Seema A Patil, Ankur Rustgi, et al.
Inflammatory Bowel Diseases|April 18, 2012
Anti-TNF therapy is associated with decreased imaging and radiation exposure in patients with Crohn's diseaseSeema A Patil, Ankur Rustgi, Sandra M Quezada, et al.
Digestive Diseases and Sciences|April 11, 2014
Racial differences in disease activity and quality of life in patients with Crohn's diseaseLeyla J Ghazi, Alison D Lydecker, Seema A Patil, et al.
Digestive Diseases and Sciences|October 13, 2018
Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's DiseaseSeema A Patil, Mark H Flasar, Jay Lin, et al.
Journal of Pharmaceutical Sciences|March 30, 2016
Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs"Soundarya Vaithianathan, Sam H Haidar, Xinyuan Zhang, et al.
Journal of Pharmaceutical Sciences|September 17, 2015
Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and AcyclovirSoundarya Vaithianathan, Sam H Haidar, Xinyuan Zhang, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Inflammatory Bowel Diseases|February 26, 2016
Biological and Immunomodulator Use in Crohn's Disease in a Medicaid PopulationMark H Flasar, Jingdong Chao, A Burak Ozbay, et al.
Gastroenterology & Hepatology|August 29, 2017
A Health Survey of Gastroenterologist Prescribing Practices of Adalimumab for Treatment of Crohn's Disease: Final ResultsSamantha Zullow, Mark H Flasar, Deborah Greenberg, et al.
World Journal of Clinical Oncology|October 26, 2017
Characteristics of <i>Clostridium difficile</i> infection in patients hospitalized with myelodysplastic syndrome or acute myelogenous leukemiaKamini Shah, Bryan F Curtin, Christopher Chu, et al.
Inflammatory Bowel Diseases|April 20, 2013
Step up versus early biologic therapy for Crohn's disease in clinical practiceLeyla J Ghazi, Seema A Patil, Ankur Rustgi, et al.
Inflammatory Bowel Diseases|April 18, 2012
Anti-TNF therapy is associated with decreased imaging and radiation exposure in patients with Crohn's diseaseSeema A Patil, Ankur Rustgi, Sandra M Quezada, et al.
Digestive Diseases and Sciences|April 11, 2014
Racial differences in disease activity and quality of life in patients with Crohn's diseaseLeyla J Ghazi, Alison D Lydecker, Seema A Patil, et al.
Digestive Diseases and Sciences|October 13, 2018
Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's DiseaseSeema A Patil, Mark H Flasar, Jay Lin, et al.
Journal of Pharmaceutical Sciences|March 30, 2016
Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs"Soundarya Vaithianathan, Sam H Haidar, Xinyuan Zhang, et al.
Journal of Pharmaceutical Sciences|September 17, 2015
Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and AcyclovirSoundarya Vaithianathan, Sam H Haidar, Xinyuan Zhang, et al.
Pageof 2